Regen BioPharma Inc (RGBP)

[art35]

Thank you--tcubed

StkMktFrk
5/29/22, 06:44 AM
$RGBP
From Insider Financial yesterday. insiderfinancial.com/4-otc-...

How much should RGBP holders endure? Well, we still think this Pink Current stock can provide great value in the long term, especially at this low price. Buying RGBP for less than a penny is the real deal, as the company can monetize its multiple patents.
RGBP is focused on the immunology and immunotherapy space. The company is working on molecule therapies for treating cancer and autoimmune disorders. On top of that, Regen is working on translational medicine platforms for the commercialization of stem cell therapies. RGBP produces stem-based medicines for diabetes, heart-related illness, circulatory issues, and Chronic Obstructive Pulmonary Disease. The stem cell industry is expected to exceed $15 billion by 2027.
As mentioned, RGBP sits on a pile of patents. Considering its extensive intellectual property portfolio, it is a matter of time before RGBP investors get rewarded.